Alnylam Pharmaceuticals ((ALNY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alnylam Pharmaceuticals is conducting a study titled ‘Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program’ to assess pregnancy outcomes in women exposed to patisiran-LNP. This study aims to gather data on pregnancy complications and fetal/neonatal outcomes, providing crucial insights into the safety of this treatment during pregnancy.
The intervention under investigation is patisiran-LNP, commercially known as ONPATTRO. This treatment is used for women with hereditary transthyretin-mediated (hATTR) amyloidosis and polyneuropathy who have been exposed to the drug during pregnancy.
This observational study follows a cohort model with a prospective time perspective. It focuses on collecting data from pregnant women exposed to patisiran-LNP, without any specific allocation or masking involved.
The study began on July 14, 2021, and is currently recruiting participants. The last update was submitted on August 25, 2025. These dates are significant as they indicate the study’s ongoing nature and the latest information available.
For investors, this update could influence Alnylam Pharmaceuticals’ stock performance by providing insights into the safety profile of patisiran-LNP, potentially affecting market confidence. Understanding the competitive landscape, particularly in the treatment of hATTR amyloidosis, is essential for assessing the broader market implications.
The study remains active, with further details accessible on the ClinicalTrials portal.